Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In DLBCL DLBCL for November/December 2020 Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies, Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL, More must reads DLBCL for September/October 2020 Survey quantifies COVID-19’s impact on oncology, More must readsDLBCL for July/August 2020 Sarcopenia is a predictor of overall survival in DLBCL patients, Mutation tied to central nervous system collapse in DLBCL, Splenectomy ideal for integrative diagnosis of splenic lymphomas, Novel STAT3 inhibitor affects DLBCL growth, FDA approves new drug for diffuse large B-cell lymphoma, More must readsDLBCL for May/June 2020 Large study identifies DLCBL patients at high risk of mortality, Tafasitamab plus lenalidomide may benefit r/r DLBCL patients ineligible for transplant, Meta-analysis indicates ibrutinib safe, effective in DLBCL, Predictive model shows high accuracy for almost all DLBCL patients, OR3A4 was upregulated in DLBCL and tied to poor prognosis, More must readsDLBCL for March/April 2020 EBV, HIV infection not associated with DLBCL subtypes, High TCL1 expression associated with poor prognosis in patients with DLBCL, Academic centers had significantly improved DLBCL survival over nonacademic centers, Developing a taxonomy of DLBCL and its subtypes with relevance to outcomes, Using informatics to identify DLCBL subgroups, drug-gene interactions, More must readsPages1 2 3 last »
